Nurix Therapeutics Inc (NASDAQ: NRIX) kicked off on Tuesday, down -1.69% from the previous trading day, before settling in for the closing price of $22.47. Over the past 52 weeks, NRIX has traded in a range of $4.22-$26.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.29%. While this was happening, its average annual earnings per share was recorded -4.40%. With a float of $63.34 million, this company’s outstanding shares have now reached $64.41 million.
Let’s determine the extent of company efficiency that accounts for 284 employees.
Nurix Therapeutics Inc (NRIX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.67%, while institutional ownership is 101.16%. The most recent insider transaction that took place on Oct 01 ’24, was worth 128,017. In this transaction Chief Legal Officer of this company sold 5,760 shares at a rate of $22.23, taking the stock ownership to the 24,592 shares. Before that another transaction happened on Oct 01 ’24, when Company’s Officer proposed sale 9,050 for $22.47, making the entire transaction worth $203,354.
Nurix Therapeutics Inc (NRIX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -4.40% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Take a look at Nurix Therapeutics Inc’s (NRIX) current performance indicators. Last quarter, stock had a quick ratio of 5.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.92, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.74 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Looking closely at Nurix Therapeutics Inc (NASDAQ: NRIX), its last 5-days average volume was 0.53 million, which is a drop from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 7.31%. Additionally, its Average True Range was 1.32.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 67.74%, which indicates a significant increase from 8.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.59% in the past 14 days, which was lower than the 67.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.09, while its 200-day Moving Average is $16.08. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $22.87. Second resistance stands at $23.65. The third major resistance level sits at $24.24. If the price goes on to break the first support level at $21.49, it is likely to go to the next support level at $20.90. Now, if the price goes above the second support level, the third support stands at $20.12.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
The company with the Market Capitalisation of 1.42 billion has total of 49,151K Shares Outstanding. Its annual sales at the moment are 76,990 K in contrast with the sum of -143,950 K annual income. Company’s last quarter sales were recorded 12,090 K and last quarter income was -44,550 K.
